Literature DB >> 29487200

Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization.

Carlo Sorrentino1,2,3, Stefania L Ciummo1,2,3, Giuseppe Cipollone4,5, Sara Caputo6, Matteo Bellone6, Emma Di Carlo7,2,3.   

Abstract

Prostate cancer stem-like cells (PCSLC) are believed to be responsible for prostate cancer onset and metastasis. Autocrine and microenvironmental signals dictate PCSLC behavior and patient outcome. In prostate cancer patients, IL30/IL27p28 has been linked with tumor progression, but the mechanisms underlying this link remain mostly elusive. Here, we asked whether IL30 may favor prostate cancer progression by conditioning PCSLCs and assessed the value of blocking IL30 to suppress tumor growth. IL30 was produced by PCSLCs in human and murine prostatic intraepithelial neoplasia and displayed significant autocrine and paracrine effects. PCSLC-derived IL30 supported PCSLC viability, self-renewal and tumorigenicity, expression of inflammatory mediators and growth factors, tumor immune evasion, and regulated chemokine and chemokine receptor genes, primarily via STAT1/STAT3 signaling. IL30 overproduction by PCSLCs promoted tumor onset and development associated with increased proliferation, vascularization, and myeloid cell recruitment. Furthermore, it promoted PCSLC dissemination to lymph nodes and bone marrow by upregulating the CXCR5/CXCL13 axis, and drove metastasis to lungs through the CXCR4/CXCL12 axis. These mechanisms were drastically hindered by IL30 knockdown or knockout in PCSLCs. Collectively, these results mark IL30 as a key driver of PCSLC behavior. Targeting IL30 signaling may be a potential therapeutic strategy against prostate cancer progression and recurrence.Significance: IL30 plays an important role in regulating prostate cancer stem-like cell behavior and metastatic potential, therefore targeting this cytokine could hamper prostate cancer progression or recurrence. Cancer Res; 78(10); 2654-68. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29487200     DOI: 10.1158/0008-5472.CAN-17-3117

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Interleukin 30 to Interleukin 40.

Authors:  Jovani Catalan-Dibene; Laura L McIntyre; Albert Zlotnik
Journal:  J Interferon Cytokine Res       Date:  2018-10       Impact factor: 2.607

2.  CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model.

Authors:  Adam L Burrack; Meagan R Rollins; Ellen J Spartz; Taylor D Mesojednik; Zoe C Schmiechen; Jackson F Raynor; Iris X Wang; Ross M Kedl; Ingunn M Stromnes
Journal:  J Immunol       Date:  2021-02-08       Impact factor: 5.426

Review 3.  Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.

Authors:  Kevin Dzobo; Dimakatso Alice Senthebane; Chelene Ganz; Nicholas Ekow Thomford; Ambroise Wonkam; Collet Dandara
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

Review 4.  Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy.

Authors:  Anna E Vilgelm; Ann Richmond
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

Review 5.  CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond.

Authors:  Marcelo G Kazanietz; Michael Durando; Mariana Cooke
Journal:  Front Endocrinol (Lausanne)       Date:  2019-07-12       Impact factor: 5.555

6.  Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.

Authors:  Carlo Sorrentino; Zhinan Yin; Stefania Ciummo; Paola Lanuti; Li-Fan Lu; Marco Marchisio; Matteo Bellone; Emma Di Carlo
Journal:  J Immunother Cancer       Date:  2019-07-31       Impact factor: 13.751

Review 7.  Current Knowledge of the Potential Links between Inflammation and Prostate Cancer.

Authors:  Tommaso Cai; Raffaella Santi; Irene Tamanini; Ilaria Camilla Galli; Gianpaolo Perletti; Truls E Bjerklund Johansen; Gabriella Nesi
Journal:  Int J Mol Sci       Date:  2019-08-06       Impact factor: 5.923

Review 8.  IL-30 (IL-27A): a familiar stranger in immunity, inflammation, and cancer.

Authors:  Booki Min; Dongkyun Kim; Matthias J Feige
Journal:  Exp Mol Med       Date:  2021-05-28       Impact factor: 12.153

Review 9.  Decoding the Role of Interleukin-30 in the Crosstalk Between Cancer and Myeloid Cells.

Authors:  Emma Di Carlo
Journal:  Cells       Date:  2020-03-04       Impact factor: 6.600

10.  Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.

Authors:  Sara Caputo; Matteo Grioni; Chiara S Brambillasca; Antonella Monno; Arianna Brevi; Massimo Freschi; Ignazio S Piras; Angela R Elia; Valentina Pieri; Tania Baccega; Angelo Lombardo; Rossella Galli; Alberto Briganti; Claudio Doglioni; Elena Jachetti; Matteo Bellone
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.